Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
Founded in 1941 in Tokyo, Japan, Hoya is a global med-tech company, and a leading ...
Founded in 1941 in Tokyo, Japan, Hoya is a glob...
For over 20 years Streamline Health has provided solutions that address the fundam...
For over 20 years Streamline Health has provide...
ReWalk Robotics (Nasdaq: RWLK) is an innovative medical device company. We design,...
ReWalk Robotics (Nasdaq: RWLK) is an innovative...
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its diffe...
Mersana Therapeutics is a clinical-stage biopha...
Alkermes plc is a fully integrated, global biopharmaceutical company developing in...
Alkermes plc is a fully integrated, global biop...
With demonstrated clinical development and commercialization expertise, VIVUS is d...
With demonstrated clinical development and comm...
Benitec is a biotechnology company developing a proprietary therapeutic technology...
Benitec is a biotechnology company developing a...
Join the National Investor Network and get the latest information with your interests in mind.